



At the dawn of a new era in treating angina pectoris, or just another antianginal drug? Some considerations about ranolazine.

<https://arctichealth.org/en/permalink/ahliterature101944>

Author: H. Balan

Author Affiliation: "Carol Davila" University of Medicine and Pharmacy, Medical Clinic, Clinical Emergency Hospital Ilfov County, Bucharest, Romania. drhoriabalan@yahoo.com

Source: Rom J Intern Med. 2010;48(4):361-9

Date: 2010

Language: English

Publication Type: Article

Keywords: Acetanilides - adverse effects - pharmacology - therapeutic use
Angina Pectoris - drug therapy
Enzyme Inhibitors - adverse effects - pharmacology - therapeutic use
Humans
Piperazines - adverse effects - pharmacology - therapeutic use
Recurrence - prevention & control

Abstract: Ranolazine is a new compound that has been approved by the FDA for use in patients who have chronic stable angina refractory to conventional antianginal medications. Ranolazine proved to be effective also as monotherapy in patients with stable angina and as part of a combination regimen. This review is inspired by the presentation that legendary figures in contemporary cardiology, such as Braunwald, Komajda and Camm made recently at the Congress of the European Society of Cardiology held in Stockholm, Sweden, last September.

PubMed ID: 21528766 [View in PubMed](#) 